GLS-012

N/A

Report date: 2023/06/20 20:00:54

Base Information

Drug NameGLS-012
Drug Alias NameGLS-012
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionLymphocyte activation gene 3 protein inhibitors
TargetsLymphocyte activation gene 3 protein
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHarbin Gloria Pharmaceuticals Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuangzhou Jishi Biotechnology Co., Ltd.
Inactive CompaniesHarbin Gloria Pharmaceuticals Co Ltd
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A